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Aims Cardiovascular magnetic resonance (CMR) has improved diagnostic and management strategies in hypertrophic cardio-
myopathy (HCM) by expanding our appreciation for the diverse phenotypic expression.We sought to characterize the
prevalence and clinical significance of a recently identified accessory left ventricular (LV) muscle bundle extending from
the apex to the basal septum or anterior wall (i.e. apical–basal).
Methods
and results
CMRwasperformed in 230 genotypedHCMpatients (48+ 15years, 69%male), 30 genotype-positive/phenotype-nega-
tive (G+/P2) family members (32+15 years, 30%male), and 126 controls. Left ventricular apical–basal muscle bundle
was identified in 145 of 230 (63%) HCMpatients, 18 of 30 (60%) G+/P2 family members, and 12 of 126 (10%) controls
(G+/P2 vs. controls; P, 0.01). In HCM patients, the prevalence of an apical–basal muscle bundle was similar among
those with disease-causing sarcomere mutations compared with patients without mutation (64 vs. 62%; P ¼ 0.88).
The presence of an LV apical–basal muscle bundle was not associated with LV outflow tract obstruction (P ¼ 0.61).
In follow-up, 33 patients underwent surgical myectomy of whom 22 (67%) were identified to have an accessory LV
apical–basal muscle bundle, which was resected in all patients.
Conclusion Apical–basalmuscle bundles are a uniquemyocardial structure commonly present inHCMpatients aswell as inG+/P2
family members and may represent an additional morphologic marker for HCM diagnosis in genotype-positive status.
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Introduction
Over the last decade, cardiovascular magnetic resonance (CMR)
has emerged as an advanced imaging technique, which provides
a comprehensive assessment of hypertrophic cardiomyopathy
(HCM) morphology.1 With tomographic, high spatial resolution
imaging, the unique imaging strengths of CMR have led to an
expanded appreciationof the heterogeneous phenotypic expression
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of HCM beyond left ventricular (LV) hypertrophy,2 and mitral valve
abnormalities3–5 to include morphologic abnormalities of the right
ventricle,6 papillary muscle architecture,7 and myocardial crypts8–10
as well as detection of fibrosis for risk assessment.11–13 By virtue of
identifying these structural abnormalities,CMRhas resolveddiagnos-
tic dilemmas, altered management strategies in patients undergoing
invasive septal reduction therapies andenhancedrisk assessment.13–15
With the growing penetration of CMR into the routine evaluation
of HCMpatients, we have observed unique and distinctive accessory
LV muscle bundles, extending from the apex to the basal anterior
septum or anterior free wall (i.e. apical–basal). Therefore, the aim
of our studywas to useCMR to characterize the prevalence and clin-
ical significance of LV apical–basal muscle bundles among a large
cohort of genotyped HCM patients, genotype-positive/phenotype-
negative (G+/P2) family members, and healthy controls.
Methods
Patient populations
The study cohort included 230 consecutive genetically tested HCM
patientswhounderwentCMRbetween1August2004and30November
2009 at three North American HCM tertiary referral centres (Tufts
MedicalCenter, Boston,MA,USA;MinneapolisHeart Institute,Minneap-
olis, MN, USA; and Toronto General Hospital, Toronto, ON, Canada).
The diagnosis of HCMwas based on demonstration by CMR of a nondi-
lated, hypertrophiedLV (maximalwall thickness≥15 mm) in the absence
of another cardiac or systemic disease that could produce themagnitude
of hypertrophy evident.16 Patients in the end-stage phase of HCM (ejec-
tion fraction ≤50%), previous alcohol septal ablation or surgical septal
myectomy, history of prior defibrillator (ICD)/pacemaker implantation
or other contraindications to CMR were excluded. In addition, no
patient had confirmed anomalous insertion of anterolateral papillary
muscle directly into anterior mitral leaflet.17,18 Clinical follow-up duration
for study patients was from the time of initial assessment during which a
CMR study was obtained, extending to the most recent evaluation
ascertained in the clinic or by telephone interview as of 30 March 2013
(median follow-up time 3.5 years (interquartile range 2.5–4.8 years).
In HCM patients, left ventricular outflow tract (LVOT) obstruction
wasdefinedby continuous-waveDoppler echocardiography as a peak in-
stantaneous outflow gradient ≥30 mmHg under resting conditions.
During the follow-upperiod, patientswhounderwent surgicalmyectomy
were identified and echocardiography, CMR, and the operative reports
were reviewed to determine whether an accessory LV apical–basal
muscle bundle was resected, as well as to clarify how the accessory
muscle bundle may have contributed to the mechanism of LVOT ob-
struction. In all patients who underwent myectomy, LVOT gradients
postmyectomy were derived from echocardiography performed at
least 3 months from operative date.
In addition, 30 G+/P2 family members (age 32+15 years; 30%male)
were recruited at theTuftsMedical Center and the TorontoGeneralHos-
pital. They were clinically asymptomatic and their maximal wall thickness
was ≤12 mm (or normal adjusted to body surface area (BSA) and age),
and no LVOT obstruction was present. During the same study period,
126 patients were assessed by clinical evaluation and CMR, without evi-
dence of cardiovascular disease at the Minneapolis Heart Institute and at
the Toronto General Hospital, and served as normal control subjects.
The studywasapprovedby theResearchEthicsBoardof theUniversity
HealthNetwork inCanada andby the InvestigationalReviewBoardof the
participating US centres and it complies with theDeclaration of Helsinki.
All authors had full access to the data, take full responsibility for its integ-
rity, and have agreed to the manuscript as written.
Cardiovascular magnetic resonance
Images from all centres were transferred to a core laboratory (PERFUSE,
Boston, MA, USA) for central, blinded analysis. Left ventricular volume,
mass and ejection fraction were measured from short-axis datasets
using standard volumetric techniques and analysed with commercially
available software (QMASSw v7.4, Medis Inc., The Netherlands).
Typical scan parameters for CMR cine imaging were as follows: standard
ECG-gated, steady-state freeprecession(SSFP), voxel size2.0 × 0.5 mm,
TR/TE 39.6/1/12 ms, flip angle 558, matrix 192 × 192, temporal
resolution ¼ 40 ms. Three-chamber SSFP sequences were prescribed
manually from basal short-axis views with multiple contiguous 8 mm
thick slices with no interslice gaps to ensure full ventricular coverage.
The LV chamber was assessed according to American Heart Associ-
ation 17 segment model. End-diastolic and end-systolic LV endocardial
and epicardial borders were manually planimetered to define the myo-
cardium, taking care to exclude papillary muscles and intertrabecular
blood pool.Maximal LVwall thicknesswasdefined as the greatest dimen-
sion at any site within the LV chamber on end-diastolic images. Left ven-
tricular volumes and mass data were indexed to BSA.
For lategadoliniumenhancement (LGE) imaging, imageacquisitionwas
performed 10–15 min after injection of 0.02 mmol/kg gadolinium con-
trast agent with 2D breath-held segmented inversion-recovery se-
quence, acquired in the same orientation as the cine SSFP images.
Quantification of LGE was performed by manually adjusting a greyscale
threshold to define areas of visually identified LGE.19 These areas were
then summed to generate a total volume of LGE and expressed as a pro-
portion of total LV mass myocardium (%LGE).
An accessory LV muscle bundle was defined in either the 2- or
3-chamber long-axis cine image as a single band of muscle extending
from apex through the LV cavity to the basal septum or anterior wall
(i.e. apical–basal) without evidence of chordal attachment to the mitral
valve (Figure 1).
The LV morphologic analysis was performed by one experienced
reader, R.C. (with 3 years of CMR experience) and reviewed and con-
firmed by a second expert reader (E.A.; with 10 years of CMR experi-
ence). The LV apical–basal muscle bundle analysis was performed by
C.G. (with 3 years of experience in CMR image interpretation) and
these readings were reviewed and confirmed by a second expert
reader (A.C.; with 15 years ofCMRexperience). Both these independent
observers were blinded to patient identity and clinical profile.
Mutational analysis
Patients were screened with laboratory-specific methods for identifica-
tion of mutations in the protein coding exons and intron/exon boundar-
ies sequencing the eightmyofilament geneswhichmost commonly cause
HCM, including: myosin-binding protein C (MYBPC3), b-myosin heavy
chain (MYH7), essential and regulatory myosin light chains (MYL2,
MYL3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3),
a-tropomyosin (TPM1), and cardiac actin (ACTC). A DNA variant was
considered disease-causing based on the following criteria: (i) an amino
acid change which is conserved among species and isoforms; (ii) the
absence of the mutation in .300 unrelated chromosomes from
healthy, ethnic-matched controls; (iii) co-segregation with affected
members in the family; and (iv) previously reported to be disease-causing
in HCM patients. Based on these criteria, the laboratory classified muta-
tions as pathogenic, presumed pathogenic, variants of unknown signifi-
cance or benign. For the purposes of this study, a pathogenic or
presumed pathogenic mutation was considered a positive genotype.20
Significance of LV apical–basal muscle bundle in HCM 2707
Reproducibility
Inter- and intraobserver variability for the presence or absence of LV
apical–basal muscle bundle was assessed from the CMR studies from
the HCM cohort of 230 patients. For interobserver variability, two
readers (A.C. and C.G.) independently assessed for the presence
or absence of muscle bundle without prior knowledge of the clinical
data, andwere blinded to the previous results. For intraobserver variabil-
ity, one reader (C.G.) independently assessed 50 randomly selected
studies for the presence or absence muscle bundles in an identical
fashion on two occasions (12 months apart), also blinded to the
clinical data.
Statistical analysis
Continuous and categorical data are expressed as mean+ SD or n (%),
respectively. Comparisons of characteristics between groups were
made with unpaired Student’s t-test, one-way ANOVA, x2 tests, or
Fisher’s exact test where appropriate for continuous and categorical
data. Adjustments for multiple comparisons were made with Scheffe’s
method or Bonferroni correction where appropriate. Reproducibility
was assessed by measure of agreements with k coefficient. A P-value of
,0.05 was considered statistically significant.
Results
Patient characteristics
Clinical, demographic, and imaging findings for the230HCMpatients,
30 G+/P2 family members, and 126 normal controls are shown
in Table 1. Hypertrophic cardiomyopathy patients were older and
more often male compared with G+/P2 family members. Genetic
test results for HCM patients and G+/P2 family members are
given in Table 2. Among HCM patients, 32% were found to have a
positive genotype, with mutations in the MYH7 and MYBPC3
genes accounting for 79% of disease-causing mutations.
Characteristics of left ventricular
apical–basal muscle bundle in
hypertrophic cardiomyopathy patients
An accessory LV apical–basal muscle bundle, identified byCMR, was
present in 145 (63%) HCM patients (Figure 1). There was no differ-
ence in the prevalence of an LV apical–basal muscle bundle among
those HCM patients found to have a disease-causing sarcomere
Figure 1 Spectrum of accessory left ventricular apical–basal muscle bundles in hypertrophic cardiomyopathy patients. (A) Accessory left ven-
tricular apical muscle bundle (arrowheads) in asymptomatic obstructed 17-year-old hypertrophic cardiomyopathy patient with minimal left ven-
tricular hypertrophy (16 mm). (B) A 64-year-old man with non-obstructive hypertrophic cardiomyopathy, maximal left ventricular wall
thickness of 18 mm and genotyped to a MYBPC3 mutation (Trp792fs) with a prominent left ventricular apical–basal muscle bundle (arrowheads).
(C) Asymptomatic 28-year-old female with non-obstructive hypertrophic cardiomyopathy with focal hypertrophy limited to the basal ventricular
septum (16 mm) and an accessory left ventricular apical–basal muscle bundle (arrowheads) traversing the left ventricular cavity from the anterior
wall to the distal portion of the chamber. (D) 33-year-oldmanwithNYHAClass III symptoms due to hypertrophic cardiomyopathy with resting left
ventricular outflow tract obstruction (70 mmHg) and maximal left ventricular wall thickness of 24 mmwith an left ventricular apical–basal muscle
bundle (arrowheads). Following CMR evaluation, patient underwent surgical myectomy for relief of left ventricular outflow tract obstruction. Ao,
aorta; LA, left atrium; LV, left ventricle; VS, ventricular septum.
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protein gene mutation (47 of 73; 64%) compared with patients with
no mutation identified (98 of 157; 62%; P ¼ 0.88).
A similar proportionof youngHCMpatients,20yearsof age (7of
12; 58%) had a muscle bundle compared with HCM patients .60
years (35 of 51; 69%; P ¼ 0.14). In addition, the prevalence of an LV
apical–basal muscle bundle was comparable across the range of
maximal LV wall thickness measurements, including in 65 of 100
patients (65%) with mild LV hypertrophy (≤18 mm) and in 18 of
26 (69%) patients with marked LV hypertrophy (≥25 mm; P ¼
0.5). Patients with hypertrophy confined only to the apex or lateral
wall also had a similar prevalence of LV apical–basal muscle
bundles compared with those with hypertrophy confined to only
the ventricular septum (apical 34 of 57; 60% vs. lateral wall 5 of 8;
63% vs. septal 106 of 165; 64%, P ¼ 0.8). There was no difference
with respect to the presence of an LV apical–basal muscle bundle
and a number of other relevant HCM disease-related variables in-
cluding: gender (P ¼ 0.66), left atrial volume indexed to BSA (P ¼
0.25), LV ejection fraction (P ¼ 0.23), or New York Heart Associ-
ation (NYHA) functional class (P ¼ 0.32). LGE was present in the
LV wall in 95 HCM patients (41%), although no patient had focal
LGE involving the LV apical–basal muscle bundle.
Left ventricular outflow tract obstruction
and surgical myectomy
There was no difference in the presence of LVOT obstruction
≥30 mmHg among HCM patients with or without an LV apical–
basal muscle bundle (30 of 145; 21% vs.15 of 85; 18%; P ¼ 0.61)
nor was there an association in patients with obstruction between
the magnitude of LVOT gradient and the presence of an apical–
basal muscle bundle (P ¼ 0.44).
However, during the follow-upperiod, 33 patients underwent sur-
gicalmyectomy for relief of LVOTobstruction, ofwhich22 (67%)had
an accessory LV apical–basal muscle bundle identified on the pre-
operative CMR study. Among these 22 HCM patients, the accessory
LV apical–basal muscle bundle was identified and resected during
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Table 1 Clinical characteristics and cardiovascular magnetic resonance findings in hypertrophic cardiomyopathy
patients, G1/P2 family members and normal controls
HCM patients G1/P2 family members Normal controls P-value*
No. of patients 230 30 126
Age at CMR (years) 48.4+15.1 31.9+14.7 40.9+16.6 ,0.0001
Male, n 158 (69%) 9 (30%) 69 (55%) ,0.0001
Body surface area (g/m2) 1.96+0.24 1.81+0.25 1.93+0.26 ,0.009
NYHAClass I/II/III/IV, n 120/89/20/1 30/0/0/0 126/0/0/0 ,0.0001
LVOT obstruction at rest (≥30mmHg), n 45 (20%) 0 0 ,0.0001
Septal reduction therapy, n 37 (16%) 0 0 ,0.0001
LV apical–basal muscle bundle, n 145 (63%) 18 (60%) 12 (10%) ,0.0001
LVEDV indexed to BSA (mL/m2) 77.5+17.1 74.8+13.0 85.3+15.3 ,0.0001
Ejection fraction (%) 66.6+8.4 64.9+4.4 62.4+6.3 ,0.0001
LA volume indexed to BSA (mL/m2) 57+23 40+9 NA ,0.0001
Maximum LV wall thickness (mm) 19.4+5 9.7+1.5 7.8+2.0 ,0.0001
LV mass indexed to BSA (g/m2) 75.9+32.9 42.7+9.6 52.8+11.5 ,0.0001
LGE present, n 95 (41.3%) NA NA NA
LGE percentage (%) 20.3+14.5 NA NA NA
Positive genotype, n 73 (32%) 30 (100%) NA ,0.0001
CMR, cardiovascular magnetic resonance; HCM, hypertrophic cardiomyopathy; G+/P2, genotype positive/phenotype negative; NYHA, New York Heart Association; LGE, late
gadolinium enhancement; LVOT, left ventricular outflow tract; LVEDV, left ventricular end-diastolic volume; LA, left atrium; LV, left ventricle.
*One P-value across all three subgroups.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Distribution of sarcomere protein gene
mutations in hypertrophic cardiomyopathy patients
and G1/P2 family members
Sarcomere
mutations
HCM patients
(n 5 73)
G1/P2 family
members (n5 30)
MYH7, n (%) 35 (48) 7 (23)
MYBPC3, n (%) 23 (32) 15 (50)
TNNT2, n (%) 5 (7) 3 (10)
TNNI3, n (%) 3 (4) 0
MYL2, n (%) 1 (1.4) 2 (7)
TPM1, n (%) 2 (2.8) 1 (3)
ACTC, n (%) 0 0
MYL3, n (%) 0 0
Multiple, n (%) 4 (5.5) 2 (7)
HCM, hypertrophic cardiomyopathy; G+/P2, genotype positive/phenotype
negative; MYH7, b-myosin heavy chain; MYBPC3, myosin-binding protein C;
TNNT2, cardiac troponin T; TNNI3, cardiac troponin I; MYL2 and 3, essential and
regulatory myosin light chains; TPM1, a-tropomyosin; ACTC, cardiac actin.
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the operation, judged by the surgeon to be contributing to themech-
anismofLVOTobstruction in the followingmanner: (i) theapical por-
tions of both the LV accessory apical–basal muscle bundle and
anterolateral papillary muscle are often fused together; (ii) the an-
terolateral papillary muscle is positioned closer to the ventricular
septum than normal, limiting its mobility during the cardiac cycle;
(iii) the abnormal position of the papillary muscle tethers the mitral
valveplane closer to thebasal portionof the ventricular septum facili-
tating motion of the anterior leaflet toward the septum by the high-
velocity ejection of blood (Figure 2).
G1/P2 family members
Similar to HCM patients, the presence of an LV apical–basal muscle
bundle identified by CMR was identified in nearly two-thirds of
G+/P2 family members (G+/P2 subjects: n ¼ 18 of 30; 60%
vs. HCM patients: n ¼ 145 of 230; 63%; P ¼ 0.9) (Figure 3), which
was significantly higher than in control subjects (n ¼ 12 of 126;
10%; P, 0.0001). Among those G+/P2 family members with an
LV apical–basal muscle bundle, MYBPC3 and MYH7 were the two
most common genes identified (50 and 23%, respectively). There
was no difference with respect to the prevalence of LV apical–
basal muscle bundles between the two most common sarcomere
genes involved in the disease process: MYBPC3: n ¼ 10 of 15
(67%) vs. MYH7: n ¼ 5 of 7 (71%); P ¼ 0.95.
Reproducibility of left ventricular
apical–basal muscle bundle
Interobserver variability showed excellent agreement in the iden-
tification of LV apical–septal muscle bundle between the two obser-
vers (k ¼ 0.937). Similarly, intraobserver variability also showed
excellent agreement for identification of LV apical–basal muscle
bundle (k ¼ 0.869).
Discussion
Over the last decade, CMR has emerged as a particularly powerful
imaging technique to characterize the diverse phenotypic expres-
sion of this genetic heart disease,4,7–10,21 leading to improved diag-
nostic and management strategies. Since performing CMR, we have
observed an unusual accessory LV muscle structure extending
fromthe apex to the basal anterior septumor basal anteriorwall (tra-
versing the LV cavity) in patients with HCM. Therefore, we felt it was
timely to assemble a large cohort of HCM patients to assess the
prevalence and clinical significance of this LV apical–basal muscle
structure among a large cohort of genotyped HCM patients.
An LV apical–basal muscle bundle was present in the majority of
HCM patients, indicating that this distinct morphologic structure of
the LVmyocardium appears to be part of the phenotypic expression
of this disease. Left ventricular apical muscle bundles proved to be
Figure 2 Artistic depiction of the contribution of left ventricular apical–basal muscle bundles to the generation of left ventricular outflow tract
obstruction. (A) Situation prior to surgicalmyectomy: (i) accessory left ventricular apical–basalmuscle bundle and the anterolateral papillarymuscle
are often fused together (at the apical portion (*)), positioning the anterolateral papillary muscle closer to the ventricular septum than normal and
limiting itsmobility away from the septumduring systole; (ii) this results in themitral valve planeoriented in closeproximity to the ventricular septum,
facilitating motion of the anterior leaflet toward the septum by the high-velocity ejection of blood. (B) Situation after surgical myectomy: by com-
pletely excising the accessorymuscle bundle, these abnormalmuscular connections are eliminated,which ultimately result in a normal orientationof
the mitral valve plane (i.e. and the leaflets coapting farther away from the basal ventricular septum).
C. Gruner et al.2710
independent of a number of demographic and clinical variables rele-
vant toHCMdiseaseexpression, includingmaximal LVwall thickness.
Indeed,HCMpatientswithmore limited expressionsof LVwall thick-
eningwere equally as likely to have an LV apical–basal muscle bundle
compared with those patients with substantial LV hypertrophy. The
high prevalence of LV apical–basal muscle bundles among G+/P2
family members (i.e. 60%) underscores the important principle that
thesemuscle bundles, in the absence of LV hypertrophy, are a poten-
tial CMR morphologic marker of genotype-positive status in family
members. Furthermore, this muscle structure was also observed
across the broad spectrumof ages, including a substantial proportion
prior to adulthood.
Our current observations, particularly the finding that muscle
bundles occur in the absence of hypertrophy in G+/P2 family
members and are present in young pre-adolescent HCM patients,
suggest that these unique morphologic structures likely represent a
congenital malformation. Other recent CMR-based observations in
patients with HCM have demonstrated a number of morphologic
abnormalities present early in development and independent of
LV hypertrophy, including anomalous insertion of the anterolateral
papillary muscle,7 elongated mitral valve leaflets,4,5 and myocardial
crypts.8–10 In total, these observations support the emerging
principle that a number of morphologic abnormalities in HCM
are likely present from birth, unlike LV hypertrophy which typically
develops during adolescence as a result of the functional
consequences caused by mutations encoding proteins of the
cardiac sarcomere.
However, we wish to be cautious in promoting LV apical–basal
muscle bundles as a specific finding in HCM, particularly since
other populationswith cardiovascular disease have not been system-
atically studied with CMR for the purposes of assessing LV apical–
basal muscle bundles. Nevertheless, in patients with equivocal LV
wall thickening and/or family history of HCM, and in whom diagnosis
remains ambiguous, the presence of an LV apical–basal muscle
bundle can provide weight toward clarifying a clinical diagnosis of
HCM.
Moreover, the observation that LV apical–basal muscle bundles
were also identified in the majority of G+/P2 family members pro-
vides further support that this unique morphologic feature likely
represents an independent and primary component of HCM
disease expression and can be considered a potential imaging
marker for genetically affected status in HCM family members in
the absence of the traditional phenotype (i.e. LV hypertrophy). In
this regard, LV apical–basal muscle bundles may alone or in combin-
ation with a variety of other structural alterations previously identi-
fied in HCM family members who carry a disease-causing
sarcomeremutation (i.e. elongatedmitral valve leaflets,4,5myocardial
crypts,8–10 LGE,22 serum biomarkers of myocardial fibrosis,23 and
echocardiographic indices of diastolic dysfunction24,25) provide a
provisional HCM diagnosis as a gene-positive carrier, thereby
Figure 3 Spectrum of accessory left ventricular apical–basal muscle bundles in four G+/P2 family members. (A) 27-year-old woman with a
normal maximum left ventricular thickness of 11 mm, and a disease-causing sarcomere protein gene mutation (MYBPC3 c.927-9G.A, intron
11). (B) 28-year-old man with a normal maximum left ventricular thickness of 9 mm, and a disease-causing MYBPC3 gene mutation
(p.Glu728X). (C) 19-year-old man with a normal maximum left ventricular thickness of 9 mm, and a disease-causing sarcomere protein gene mu-
tation (MYH7 p.Gly741.Trp). (D) 42-year-old woman with a normal maximum left ventricular thickness of 12 mm, and a disease-causing MYBPC3
mutation (p.Arg502Trp). Ao, aorta; LA, left atrium; LV, left ventricle.
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prompting strong consideration for obtaining a confirmatory diagno-
sis with genetic testing.16
The presence of an accessory LV apical–basal muscle bundle may
also have implications for clinical management strategies. In the ma-
jority of patients undergoing surgical myectomy for relief of LVOT
obstruction, an LV apical–basal muscle bundle was identified by
the surgeon intraoperatively as a contributing factor to the mechan-
ism of LVOT obstruction, and as a result completely resected during
theoperation. Byoperativeexcisionof the accessorymuscle bundles,
the abnormal muscular connections were eliminated, ultimately
resulting in a normal orientation of the mitral valve plane (i.e. with
the leaflets coapting farther away from the basal ventricular
septum).26,27 Therefore, by reliably identifying LV apical–basal
muscle bundles, as well as other abnormalities of the mitral valve
and subvalvular structure which can also contribute to LVOT ob-
struction (i.e. elongated mitral valve leaflets, accessory and apically
placed papillary muscles, and anomalous insertion of the papillary
muscle), preoperative CMR can provide important morphologic
data to aid in surgical planning and strategy.
In this study, we usedCMR to systematically evaluate for the pres-
ence of LV apical–basal muscles bundles in patients with HCM, as it
has been our experience that 2D transthoracic echocardiography is
often not capable of reliably detecting this particular structural ab-
normality. Indeed, LV apical–basal muscle bundles have largely
gone unrecognized until the emergence of CMR, due to the fact
that this narrow, thin structure is often confined predominantly to
the distal portion of the LV chamber. This is similar to other observa-
tions with CMR in which other morphologic abnormalities of the
distal portion of the LV chambermay not bewell seen with echocar-
diography including focal hypertrophy confined to the apex or apical
aneurysms. The unique imaging strengths ofCMR,with its high spatial
resolution and ability to generate images with sharp contrast
between bright blood pool and dark myocardium, is particularly
well suited to reliably identify this muscle structure.
Limitations
The present HCM cohort was assembled in a consecutive fashion,
but with enrolment defined by eligibility for CMR. Therefore, a
certaindegreeofpreferencewith respect topatient selectionwasun-
avoidable within our study design. In addition, the size of our control
population was limited and may not be completely representative of
the generalpopulation.These featuresofour studydesign andpatient
selection may influence the generalizability of these data to the
broader HCM patient population.
In conclusion, these CMR-based observations demonstrate that
LV apical–basal muscle bundles are commonly identified in HCM
patients and genotype-positive/phenotype-negative members and
may represent a primary morphologic feature which further
expands our appreciation for the diverse phenotypic expression of
this genetic heart disease. The presence of an LV apical–basal
muscle bundle can prompt confirmatory genetic testing in family
memberswithoutLVhypertrophyandwhen identifiedpreoperatively,
may alter surgical planning.
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Transapical myectomy for severe mid-ventricular obstructive hypertrophic
cardiomyopathy
Kevin C. Ong1, Jeffrey B. Geske1, Hartzell V. Schaff2, and Rick A. Nishimura1*
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* Corresponding author. Tel: +1 5072848342, Fax: +1 5072667929, Email: rnishimura@mayo.edu
An 83-year-old woman with hypertrophic cardio-
myopathy was referred with progressive exertional
dyspnoea. Shehadmarked apical andmid-ventricular
hypertrophywithmid-ventricular obstruction and a
small apical aneurysm (Panels A1–3, Supplementary
material online, Video S1). Doppler echocardiog-
raphy through the left ventricle (Panel B1) identified
an early peak systolic gradient of 36 mmHg (Panel
B1), mid-systolic cessation of flow (Panel B2), fol-
lowed by re-emergence of forward flow in late
systole and continuing into early diastole (paradox-
ical flow) (Panel B3). Cardiac catheterization de-
monstrated a 184 mmHg mid-ventricular gradient
(Panel D), pulmonary artery wedge pressure of
32 mmHg, and normal coronaries. She underwent
apical and mid-ventricular myectomy (Panels C1–3)
which resulted in symptom improvement.
Flow through an areaof obstruction is required in
order to derive a Doppler pressure gradient. In our
patient, complete mid-ventricular obstruction led
to mid-systolic flow cessation through the left ven-
tricular cavity and the absence of a Doppler signal to determine a pressure gradient. Therefore, the true peak mid-ventricular pressure
gradient recorded on haemodynamic catheterization occurred during apical mid-systolic isovolumic contraction when cavity obliteration
prevented ejection of flow from the apex (Panels B1 andD1–2). This supports the concept that significant elevations in apical intracavitary
pressure due to severemid-ventricular obstructionmay contribute to the genesis of an apical aneurysm. Therefore, non-invasiveDoppler
echocardiographymay significantly underestimate themagnitude of mid-ventricular obstruction. Mid-ventricular myectomy relieves mid-
ventricularobstruction, and, in patientswith significant secondaryelevations in pulmonary arterywedgepressure, improves diastolic filling.
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